DRUG

Business Context and Reporting Period

Company: Bright Minds Biosciences Inc. (Nasdaq: DRUG)
Filing Type: Annual Report on Form 20-F
Reporting Period: Fiscal year ended September 30, 2024
Business Overview: A clinical-stage biotechnology company developing selective serotonergic therapeutics for neurological and psychiatric disorders, including epilepsy and depression. The company has no commercial revenue and relies on equity financing to fund operations.

Key Financial Metrics

Note: Financial statements are prepared in Canadian Dollars (CAD) in accordance with IFRS.

Material Changes vs. Prior Period

• Reduced Net Loss: The net loss decreased by approximately 62% to $2.8 million from $7.4 million in the prior year, primarily driven by a significant reduction in Research and Development (R&D) expenses.
• R&D Expense Decline: R&D expenses dropped from $5.0 million in 2023 to $1.2 million in 2024. This decrease is attributed to the completion of certain R&D activities in the prior year and a more focused ongoing research strategy.
• Expense Management: Consulting fees decreased by $109,000 and marketing/investor relations expenses decreased by $78,000 due to the discontinuation of specific services and activities.
• Professional Fees Increase: Professional fees increased by $110,000 due to increased business activity and regulatory requirements.
• Share Capital: Issued share capital increased due to a private placement of common shares and the exercise of pre-funded warrants and RSUs during the fiscal year.

Outlook, Risks, and Management Commentary

Guidance and Outlook

• Financing Needs: Management anticipates incurring losses for the fiscal year ending September 30, 2025. Continued operations depend on the ability to raise additional capital through equity financings.
• Subsequent Financing: Following the reporting period, the company completed a non-brokered private placement in November 2024 raising approximately US$35 million (CAD equivalent not explicitly stated in summary, but noted as significant). Management believes current working capital is sufficient to fulfill business objectives.
• Clinical Progress: Phase 2 clinical trials for the lead candidate BMB-101 (for Absence Epilepsy and Developmental Epileptic Encephalopathy) were initiated in 2024. IND-enabling studies are ongoing for other candidates (BMB-201, BMB-202).

Risks and Contingencies

• Going Concern: The company has a history of losses and negative operating cash flows. There is no assurance that additional financing will be available on acceptable terms.
• Clinical Trial Risks: High risk of failure in clinical trials, potential delays in regulatory approvals (FDA/Health Canada), and the possibility of adverse safety events.
• Legal Proceedings: A claim was filed by the former Chief Medical Officer, Dr. Revati Shreeniwas, regarding termination compensation. The trial is scheduled for June 2025.
• Intellectual Property: Reliance on licensed patents from the University of Illinois; risks include patent expiration, challenges to validity, and inability to enforce rights globally.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $5.7 million cash balance against projected burn rates, considering the recent US$35 million private placement.
• Clinical Trial Status: Confirm the enrollment status and preliminary data from the Phase 2 "BREAKTHROUGH" study for BMB-101.
• Legal Exposure: Monitor the outcome of the pending litigation with the former CMO scheduled for mid-2025.
• Dilution Risk: Assess the impact of outstanding options (340,400), warrants (916,815), and RSUs (192,000) on future share count and ownership dilution.
• Regulatory Milestones: Track the timeline for IND submissions for secondary candidates (BMB-201, BMB-202) and potential FDA interactions.